Human IFN-beta Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB8141
Key Product Details
Species Reactivity
Human
Applications
Immunocytochemistry, Neutralization
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2B Clone # 937912
Product Specifications
Immunogen
Chinese hamster ovary cell line CHO-derived recombinant human IFN‑ beta
Specificity
Detects human IFN‑ beta in direct ELISAs.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human IFN-beta Antibody
IFN‑ beta in A549 Human Cell Line.
IFN-beta was detected in immersion fixed A549 human lung carcinoma cell line using Mouse Anti-Human IFN-beta Monoclonal Antibody (Catalog # MAB8141) at 8 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.
IFN-beta Inhibition of EMCV-induced Cytopathy and Neutralization by Human IFN-beta Antibody.
Recombinant Human IFN-beta (Catalog # 8499-IF) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IFN-beta (50 pg/mL) is neutralized (green line) by increasing concentrations of Human IFN-beta Monoclonal Antibody (Catalog # MAB8141). The ND50 is typically 0.2-1.2 µg/mL.Applications for Human IFN-beta Antibody
Application
Recommended Usage
Immunocytochemistry
8-25 µg/mL
Sample: Immersion fixed A549 human lung carcinoma cell line
Sample: Immersion fixed A549 human lung carcinoma cell line
Neutralization
Measured by its ability to neutralize IFN‑ beta inhibition of EMCV-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129. The Neutralization Dose (ND50) is typically 0.2-1.2 µg/mL in the presence of 50 pg/mL Recombinant Human IFN‑ beta.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IFN-beta
IFN-beta (interferon beta; also fibroblast IFN) is a secreted, monomeric 23-24 kDa member of the alpha/beta interferon family of molecules. It can be produced by almost all cell types in response to bacterial DNA or viral double-stranded RNA and is abundantly secreted by circulating plasmacytoid DCs. IFN-beta drives monocytic transformation into DCs, and it appears to stimulate a B cell switch from from IgM to IgG secretion. Mature human IFN-beta is 166 amino acids (aa) in length (aa 22-187) and contains one phosphorylation site at Ser140. There is one potential alternative start site at Met22. Full-length human IFN-beta (aa 22-187) shares 47% aa identity with mouse IFN-beta.
Long Name
Interferon beta
Alternate Names
IFB, IFF, IFNB, IFNB1, IFNbeta
Gene Symbol
IFNB1
Additional IFN-beta Products
Product Documents for Human IFN-beta Antibody
Product Specific Notices for Human IFN-beta Antibody
For research use only
Loading...
Loading...
Loading...
Loading...